Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Effects of live yeast on differential genetic and functional attributes of rumen microbiota in beef cattle.

Ogunade IM, Lay J, Andries K, McManus CJ, Bebe F.

J Anim Sci Biotechnol. 2019 Sep 4;10:68. doi: 10.1186/s40104-019-0378-x. eCollection 2019.

2.

Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.

Kaushik A, Ammerman NC, Tyagi S, Saini V, Vervoort I, Lachau-Durand S, Nuermberger E, Andries K.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e00007-19. doi: 10.1128/AAC.00007-19. Print 2019 Apr.

3.

Monensin Alters the Functional and Metabolomic Profile of Rumen Microbiota in Beef Cattle.

Ogunade I, Schweickart H, Andries K, Lay J, Adeyemi J.

Animals (Basel). 2018 Nov 17;8(11). pii: E211. doi: 10.3390/ani8110211.

4.

Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial.

Meyvisch P, Kambili C, Andries K, Lounis N, Theeuwes M, Dannemann B, Vandebosch A, Van der Elst W, Molenberghs G, Alonso A.

PLoS One. 2018 Jul 19;13(7):e0200539. doi: 10.1371/journal.pone.0200539. eCollection 2018.

5.

Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units.

Choi PJ, Sutherland HS, Tong AST, Blaser A, Franzblau SG, Cooper CB, Lotlikar MU, Upton AM, Guillemont J, Motte M, Queguiner L, Andries K, Van den Broeck W, Denny WA, Palmer BD.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5190-5196. doi: 10.1016/j.bmcl.2017.10.042. Epub 2017 Oct 20.

6.

6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis.

Tong AST, Choi PJ, Blaser A, Sutherland HS, Tsang SKY, Guillemont J, Motte M, Cooper CB, Andries K, Van den Broeck W, Franzblau SG, Upton AM, Denny WA, Palmer BD, Conole D.

ACS Med Chem Lett. 2017 Sep 22;8(10):1019-1024. doi: 10.1021/acsmedchemlett.7b00196. eCollection 2017 Oct 12.

7.

In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria.

Aguilar-Ayala DA, Cnockaert M, André E, Andries K, Gonzalez-Y-Merchand JA, Vandamme P, Palomino JC, Martin A.

J Med Microbiol. 2017 Aug;66(8):1140-1143. doi: 10.1099/jmm.0.000537. Epub 2017 Jul 28.

8.

Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.

Furin J, Diacon AH, Andries K.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):4-5. doi: 10.5588/ijtld.16.0768. No abstract available.

PMID:
28157457
9.

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.

Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, Andries K.

J Antimicrob Chemother. 2017 Mar 1;72(3):684-690. doi: 10.1093/jac/dkw502.

10.

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice.

Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, Chen C, Reichlen MJ, Asay BC, Voskuil MI, Nuermberger EL, Andries K, Lyons MA, Dartois V, Lenaerts AJ.

ACS Infect Dis. 2016 Apr 8;2(4):251-267. Epub 2016 Feb 24.

11.

In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis.

Lounis N, Vranckx L, Gevers T, Kaniga K, Andries K.

Med Mal Infect. 2016 Jun;46(4):220-5. doi: 10.1016/j.medmal.2016.04.007.

PMID:
27210281
12.

Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.

Almeida D, Ioerger T, Tyagi S, Li SY, Mdluli K, Andries K, Grosset J, Sacchettini J, Nuermberger E.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4590-9. doi: 10.1128/AAC.00753-16. Print 2016 Aug.

13.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group.

Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.

14.

Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models.

Obregón-Henao A, Arnett KA, Henao-Tamayo M, Massoudi L, Creissen E, Andries K, Lenaerts AJ, Ordway DJ.

Antimicrob Agents Chemother. 2015 Nov;59(11):6904-12. doi: 10.1128/AAC.00459-15. Epub 2015 Aug 24.

15.

The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress.

Lu P, Heineke MH, Koul A, Andries K, Cook GM, Lill H, van Spanning R, Bald D.

Sci Rep. 2015 May 27;5:10333. doi: 10.1038/srep10333.

16.

Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model.

Ispas G, Koul A, Verbeeck J, Sheehan J, Sanders-Beer B, Roymans D, Andries K, Rouan MC, De Jonghe S, Bonfanti JF, Vanstockem M, Simmen K, Verloes R.

PLoS One. 2015 May 26;10(5):e0126959. doi: 10.1371/journal.pone.0126959. eCollection 2015.

17.

Bactericidal mode of action of bedaquiline.

Hards K, Robson JR, Berney M, Shaw L, Bald D, Koul A, Andries K, Cook GM.

J Antimicrob Chemother. 2015 Jul;70(7):2028-37. doi: 10.1093/jac/dkv054. Epub 2015 Mar 8.

PMID:
25754998
18.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group.

N Engl J Med. 2014 Aug 21;371(8):723-32. doi: 10.1056/NEJMoa1313865.

19.

Acquired resistance of Mycobacterium tuberculosis to bedaquiline.

Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A.

PLoS One. 2014 Jul 10;9(7):e102135. doi: 10.1371/journal.pone.0102135. eCollection 2014.

20.

The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatis.

Lu P, Villellas C, Koul A, Andries K, Lill H, Bald D.

J Antibiot (Tokyo). 2014 Dec;67(12):835-7. doi: 10.1038/ja.2014.74. Epub 2014 Jun 11. No abstract available.

PMID:
24916895
21.

Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism.

Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D.

Nat Commun. 2014 Feb 26;5:3369. doi: 10.1038/ncomms4369.

22.

Towards a new combination therapy for tuberculosis with next generation benzothiazinones.

Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, Ryabova OB, Vocat A, Decosterd LA, Widmer N, Buclin T, Bitter W, Andries K, Pojer F, Dyson PJ, Cole ST.

EMBO Mol Med. 2014 Mar;6(3):372-83. doi: 10.1002/emmm.201303575. Epub 2014 Feb 5.

23.

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ.

Tuberculosis (Edinb). 2012 Nov;92(6):453-88. doi: 10.1016/j.tube.2012.07.003. Epub 2012 Aug 30. Review.

24.

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Sacksteder KA, Protopopova M, Barry CE 3rd, Andries K, Nacy CA.

Future Microbiol. 2012 Jul;7(7):823-37. doi: 10.2217/fmb.12.56. Review.

25.

Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria.

Balemans W, Vranckx L, Lounis N, Pop O, Guillemont J, Vergauwen K, Mol S, Gilissen R, Motte M, Lançois D, De Bolle M, Bonroy K, Lill H, Andries K, Bald D, Koul A.

Antimicrob Agents Chemother. 2012 Aug;56(8):4131-9. doi: 10.1128/AAC.00273-12. Epub 2012 May 21.

26.

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. doi: 10.1128/AAC.00384-12. Epub 2012 Apr 2.

27.

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF.

Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6. doi: 10.1128/AAC.06126-11. Epub 2012 Mar 5.

28.

Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.

Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K.

Antimicrob Agents Chemother. 2012 Mar;56(3):1444-51. doi: 10.1128/AAC.00720-11. Epub 2011 Dec 12.

29.

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92. doi: 10.1128/AAC.05293-11. Epub 2011 Sep 19.

30.

Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.

Guillemont J, Meyer C, Poncelet A, Bourdrez X, Andries K.

Future Med Chem. 2011 Sep;3(11):1345-60. doi: 10.4155/fmc.11.79.

PMID:
21879841
31.

Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase.

Haagsma AC, Podasca I, Koul A, Andries K, Guillemont J, Lill H, Bald D.

PLoS One. 2011;6(8):e23575. doi: 10.1371/journal.pone.0023575. Epub 2011 Aug 17.

32.

Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.

Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL.

Am J Respir Crit Care Med. 2011 Sep 15;184(6):732-7. doi: 10.1164/rccm.201103-0397OC. Epub 2011 Jun 9.

33.

Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.

Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V.

PLoS One. 2011 Mar 3;6(3):e17556. doi: 10.1371/journal.pone.0017556.

34.

The challenge of new drug discovery for tuberculosis.

Koul A, Arnoult E, Lounis N, Guillemont J, Andries K.

Nature. 2011 Jan 27;469(7331):483-90. doi: 10.1038/nature09657. Review.

PMID:
21270886
35.

Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model.

Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, Van Kerckhove B, Roymans D, De Meulder M, Rouan MC, Van Remoortere P, Bonfanti JF, Van Velsen F, Koul A, Vanstockem M, Andries K, Sowinski P, Wang B, Openshaw P, Verloes R.

Eur Respir J. 2011 Aug;38(2):401-8. doi: 10.1183/09031936.00005610. Epub 2010 Dec 9.

36.

Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.

Rouan MC, Gevers T, Roymans D, de Zwart L, Nauwelaers D, De Meulder M, van Remoortere P, Vanstockem M, Koul A, Simmen K, Andries K.

Antimicrob Agents Chemother. 2010 Nov;54(11):4534-9. doi: 10.1128/AAC.00643-10. Epub 2010 Sep 7.

37.

Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents.

Diacon AH, Maritz JS, Venter A, van Helden PD, Andries K, McNeeley DF, Donald PR.

Eur J Clin Microbiol Infect Dis. 2010 Dec;29(12):1561-5. doi: 10.1007/s10096-010-1043-7. Epub 2010 Sep 4.

PMID:
20820832
38.

Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.

Dhillon J, Andries K, Phillips PP, Mitchison DA.

Tuberculosis (Edinb). 2010 Sep;90(5):301-5. doi: 10.1016/j.tube.2010.07.004. Epub 2010 Aug 21.

PMID:
20732832
39.

Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.

Andries K, Gevers T, Lounis N.

Antimicrob Agents Chemother. 2010 Nov;54(11):4540-4. doi: 10.1128/AAC.00934-10. Epub 2010 Aug 16.

40.

In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.

Reddy VM, Einck L, Andries K, Nacy CA.

Antimicrob Agents Chemother. 2010 Jul;54(7):2840-6. doi: 10.1128/AAC.01601-09. Epub 2010 Apr 12.

41.

Essentiality of FASII pathway for Staphylococcus aureus.

Balemans W, Lounis N, Gilissen R, Guillemont J, Simmen K, Andries K, Koul A.

Nature. 2010 Jan 21;463(7279):E3; discussion E4. doi: 10.1038/nature08667.

PMID:
20090698
42.

Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.

Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI.

Antimicrob Agents Chemother. 2010 Mar;54(3):1022-8. doi: 10.1128/AAC.01611-09. Epub 2009 Dec 28.

43.

Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein.

Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, Verheyen N, Kim H, Willebrords R, Bonfanti JF, Bruinzeel W, Cummings MD, van Vlijmen H, Andries K.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):308-13. doi: 10.1073/pnas.0910108106. Epub 2009 Dec 4.

44.

[R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].

Lounis N, Guillemont J, Veziris N, Koul A, Jarlier V, Andries K.

Med Mal Infect. 2010 Jul;40(7):383-90. doi: 10.1016/j.medmal.2009.09.007. Epub 2009 Dec 1. Review. French.

PMID:
19954909
45.

ATP synthase inhibition of Mycobacterium avium is not bactericidal.

Lounis N, Gevers T, Van den Berg J, Vranckx L, Andries K.

Antimicrob Agents Chemother. 2009 Nov;53(11):4927-9. doi: 10.1128/AAC.00689-09. Epub 2009 Sep 8.

46.

Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.

Guillemont J, Benjahad A, Oumouch S, Decrane L, Palandjian P, Vernier D, Queguiner L, Andries K, de Béthune MP, Hertogs K, Grierson DS, Nguyen CH.

J Med Chem. 2009 Dec 10;52(23):7473-87. doi: 10.1021/jm900802y.

PMID:
19645483
47.

The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently.

Gelber R, Andries K, Paredes RM, Andaya CE, Burgos J.

Antimicrob Agents Chemother. 2009 Sep;53(9):3989-91. doi: 10.1128/AAC.00722-09. Epub 2009 Jul 13.

48.

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N.

Am J Respir Crit Care Med. 2009 Sep 15;180(6):553-7. doi: 10.1164/rccm.200807-1152OC. Epub 2009 Jul 9.

PMID:
19590024
49.

The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF.

N Engl J Med. 2009 Jun 4;360(23):2397-405. doi: 10.1056/NEJMoa0808427.

50.

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue.

Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, Andries K, Lill H, Koul A, Bald D.

Antimicrob Agents Chemother. 2009 Mar;53(3):1290-2. doi: 10.1128/AAC.01393-08. Epub 2008 Dec 15.

Supplemental Content

Loading ...
Support Center